https://scholars.lib.ntu.edu.tw/handle/123456789/470378
標題: | Predictive and prognostic values of tau and ERCC1 in advanced breast cancer patients treated with paclitaxel and cisplatin | 作者: | YU-YUN SHAO KUAN-TING KUO Hu F.-C. YEN-SHEN LU CHIUN-SHENG HUANG JAU-YU LIAU Lee W.-C. CHIUN HSU WEN-HUNG KUO KING-JEN CHANG CHING-HUNG LIN ANN-LII CHENG |
公開日期: | 2010 | 卷: | 40 | 期: | 4 | 起(迄)頁: | 286-293 | 來源出版物: | Japanese Journal of Clinical Oncology | 摘要: | Objective: We studied tau and excision repair cross-complementing 1 expression to evaluate their predictive values in advanced breast carcinoma patients. Methods: Patients treated with paclitaxel and cisplatin as the first-line chemotherapy for locally advanced or metastatic breast cancer were enrolled. The expression levels of tau and excision repair cross-complementing 1 were assessed by immunohistochemistry and examined for their associations with treatment response and survival. Results: Fifty-four patients were included in this study. Despite the strong association between tau expression and lower histological grade and estrogen receptor expression, tau expression remained an independent predictor for a lower response rate in multivariate analysis (odd ratio = 0.24, P = 0.02). However, tau expression was a predictor for longer overall survival in both univariate analysis (median, 57.5 vs. 30.4 months, P = 0.02) and multivariate analysis (hazard ratio = 0.36, P = 0.008). Excision repair cross-complementing 1 was not associated with treatment response or overall survival. Conclusions: Tau expression but not excision repair cross-complementing 1 in advanced breast cancer predicts poor response to combination chemotherapy of paclitaxel and cisplatin. However, tau expression is significantly associated with longer overall survival. ? The Author (2010). Published by Oxford University Press. All rights reserved. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-77951241525&doi=10.1093%2fjjco%2fhyp184&partnerID=40&md5=b0b4679eca06c9993866930317fbde99 https://scholars.lib.ntu.edu.tw/handle/123456789/470378 |
ISSN: | 0368-2811 | DOI: | 10.1093/jjco/hyp184 | SDG/關鍵字: | cisplatin; estrogen receptor; excision repair cross complementing protein 1; hormone; paclitaxel; progesterone receptor; tau protein; antineoplastic agent; cisplatin; DNA binding protein; endonuclease; ERCC1 protein, human; paclitaxel; tau protein; tumor marker; adjuvant therapy; adult; advanced cancer; aged; article; breast carcinoma; cancer adjuvant therapy; cancer combination chemotherapy; cancer grading; clear cell carcinoma; drug dose regimen; drug dose sequence; gene expression; human; immunohistochemistry; low drug dose; major clinical study; mucinous carcinoma; multiple cycle treatment; overall survival; prediction; prognosis; survival time; treatment response; biosynthesis; breast tumor; disease free survival; drug resistance; female; genetics; Kaplan Meier method; metabolism; middle aged; phase 2 clinical trial; retrospective study; treatment outcome; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Clinical Trials, Phase II as Topic; Disease-Free Survival; DNA-Binding Proteins; Drug Resistance, Neoplasm; Endonucleases; Female; Humans; Immunohistochemistry; Kaplan-Meiers Estimate; Middle Aged; Paclitaxel; Prognosis; Retrospective Studies; tau Proteins; Treatment Outcome; Tumor Markers, Biological |
顯示於: | 病理學科所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。